All conditions

Hepatitis B

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

1695
Trials on record
124
Recruiting now
5
Australian sites
7
Phase 3 trials
3
PBS medicines
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Hepatitis B →

Get alerts when Hepatitis B trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Hepatitis B

Hepatitis B is a viral infection that affects the liver. It is caused by the hepatitis B virus (HBV), which can be passed from one person to another through blood, sexual contact, or from a mother to her baby during birth. Some people who are infected clear the virus from their body within a few months — this is called acute hepatitis B. Others carry the virus long-term, which is known as chronic hepatitis B. Many people with chronic hepatitis B feel completely well for years and may not notice any symptoms, but the virus can still quietly affect the liver over time, which is why regular monitoring matters.

In Australia, it is estimated that around 200,000 people are living with chronic hepatitis B. The condition is more common in people who were born in countries where hepatitis B is widespread, particularly parts of Asia, the Pacific Islands, and sub-Saharan Africa. Aboriginal and Torres Strait Islander communities are also disproportionately affected. Hepatitis B is not spread through everyday contact like hugging, sharing food, or coughing, so people living with the virus can lead full and active lives.

Treatment and care for hepatitis B is managed by a doctor, often with support from a specialist such as a gastroenterologist or infectious disease physician. Not everyone with chronic hepatitis B needs antiviral medication straight away — some people are monitored regularly through blood tests and liver checks, while others may be prescribed antiviral tablets to help keep the virus under control and reduce the risk of liver damage. A doctor will look at each person's individual situation to work out the most appropriate plan for them.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Hepatitis B in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

PBS-subsidised medicines for Hepatitis B

3 medicines listed on the PBS for Hepatitis B. Filter by authority type, or open the full table below.

What the authority types mean Unrestricted: no clinical criteria; a doctor can prescribe it on the PBS for any appropriate use. Restricted benefit: subsidised only for the specific conditions or uses set out by the PBS. Streamlined authority: restricted, but the doctor does not need prior approval; they record a streamlined authority code confirming you meet the criteria. Authority required: restricted, and the doctor must get prior approval from Services Australia (by phone or online) before it is subsidised. Source: Pharmaceutical Benefits Scheme (pbs.gov.au).
Full PBS medicines table 3 listed

These medicines are listed on the Pharmaceutical Benefits Scheme (PBS) for the specific indications shown. A listing does not mean a medicine is right for you; your doctor decides what is appropriate. Prices shown are the PBS-determined dispensed price. Most patients pay only the standard co-payment, up to AU$25.00 per script (general) or AU$7.70 (concession or Safety Net) in 2026, with the Australian Government subsidising the rest.

Medicine Brand(s) Listed for
Entecavir ENTECAVIR RBX hepatitis B infection AU$26.35 Streamlined authority
Lamivudine Zeffix hepatitis B infection AU$23.44 Streamlined authority
tenofovir disoproxil Tenofovir GH, Tenofovir Disoproxil Viatris, Tenofovir Sandoz hepatitis B infection AU$38.96 Streamlined authority

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Research pipeline

Where trials for Hepatitis B currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Hepatitis B.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Hepatitis B by country. Australia is highlighted.

Showing the top 10 of 48 countries with trial sites.

Clinical trials for Hepatitis B

Showing 140 of 140 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT00076336 · Novartis Pharmaceuticals Phase 3 · 21 countries Completed
Completed Phase 3 Est. completion 1 December 2009
🇦🇺 AU🇨🇦 CA🇨🇳 CN🇫🇷 FR🇩🇪 DE🇮🇳 IN🇮🇱 IL🇱🇻 LV +13 more

Who might be able to join this trial: - You have been diagnosed with long-term (chronic) hepatitis B that has caused serious liver problems, meaning your liver is no longer working properly (this is called "decompensated" hepatitis B) - A doctor has assessed your liver condition using a scoring system called the Child-...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT00410072 · Bristol-Myers Squibb Phase 3 · 13 countries Completed
Completed Phase 3 Est. completion 1 October 2010
🇦🇷 AR🇦🇺 AU🇧🇷 BR🇨🇦 CA🇫🇷 FR🇮🇳 IN🇮🇹 IT🇲🇽 MX +5 more

**Who might be able to join this trial:** - You have been diagnosed with a long-term (chronic) Hepatitis B virus infection, whether a specific protein marker called "e antigen" is present in your blood or not - You have never previously been treated with a type of antiviral medication called nucleoside or nucleotide dr...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT00927082 · Hoffmann-La Roche Phase 4 · 10 countries Completed
Completed Phase 4 Est. completion 1 November 2014
🇦🇺 AU🇧🇷 BR🇨🇳 CN Hong Kong🇳🇿 NZ🇷🇺 RU🇸🇬 SG🇰🇷 KR +2 more

Who might be able to join this trial: - You must have given your informed consent to participate in the related study called WV19432 - You must have already completed both the treatment and the follow-up period in study WV19432 Who may not be able to join: - Anyone who would not have been eligible for the original stu...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
🇦🇺 NCT01277601 · Gilead Sciences Phase 4 · 19 countries Completed
Completed Phase 4 Est. completion 1 August 2014
🇦🇺 AU🇨🇦 CA🇫🇷 FR🇩🇪 DE🇬🇷 GR Hong Kong🇮🇳 IN🇮🇹 IT +11 more

**Who might be able to join this trial:** - Adults between 18 and 75 years old who have had a long-term hepatitis B infection (confirmed by blood tests) for at least 6 months - People who have never taken anti-hepatitis B medication, OR people who took oral hepatitis B medication but stopped at least 24 weeks before th...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
🇦🇺 NCT01519960 · Hoffmann-La Roche Phase 3 · 12 countries Completed
Completed Phase 3 Est. completion 9 July 2015
🇦🇺 AU🇧🇪 BE🇧🇬 BG🇨🇳 CN🇩🇪 DE🇮🇱 IL🇮🇹 IT🇵🇱 PL +4 more

Who might be able to join this trial: - You are male or female, between 3 years old and under 18 years old at the start of the trial - You have had a positive test for hepatitis B surface antigen (a sign of hepatitis B infection) for more than 6 months - You have a positive HBeAg test and detectable hepatitis B virus i...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01940341 · Gilead Sciences Phase 3 · 17 countries Completed
Completed Phase 3 Est. completion 30 September 2015
🇦🇺 AU🇨🇦 CA🇫🇷 FR Hong Kong🇮🇳 IN🇮🇹 IT🇯🇵 JP🇳🇿 NZ +9 more

**Who might be able to join this trial:** - You are able to understand and agree to the study terms by signing a consent form before anything begins. - You are an adult male, or a female who is not pregnant or breastfeeding. - You have been diagnosed with a long-term (chronic) hepatitis B virus (HBV) infection. - Your...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01940471 · Gilead Sciences Phase 3 · 19 countries Completed
Completed Phase 3 Est. completion 16 November 2015
🇦🇺 AU🇧🇬 BG🇨🇦 CA🇫🇷 FR Hong Kong🇮🇳 IN🇮🇹 IT🇯🇵 JP +11 more

**Who might be able to join this trial:** - You must be able to understand and sign a consent form before any study procedures begin. - You must be an adult male, or a female who is not pregnant or breastfeeding. - You must have a confirmed, long-term (chronic) hepatitis B virus (HBV) infection. - Your hepatitis B mus...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02263079 · Hoffmann-La Roche Phase 3 · 12 countries Completed
Completed Phase 3 Est. completion 29 January 2020
🇦🇺 AU🇧🇪 BE🇩🇪 DE🇮🇹 IT🇲🇾 MY🇷🇴 RO🇷🇺 RU🇹🇼 TW +4 more

**Who might be able to join this trial:** - You have tested positive for two specific hepatitis B markers (called HBsAg and HBeAg) for more than 6 months before the study starts. - Blood tests show a measurable level of hepatitis B virus in your blood (above a certain amount), confirmed on at least 2 separate occasion...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02422264 · GlaxoSmithKline Phase 4 · 6 countries Completed
Completed Phase 4 Est. completion 7 March 2018
🇦🇺 AU🇨🇦 CA🇨🇿 CZ🇫🇮 FI🇮🇹 IT🇪🇸 ES

**Who might be able to join this trial:** - The parent or legal guardian must be willing and able to follow the study requirements, such as filling in diary cards and attending follow-up visits. - The parent or legal guardian must give written consent before any study procedures take place. - The child must be between...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
🇦🇺 NCT02853929 · GlaxoSmithKline Phase 4 · 6 countries Completed
Completed Phase 4 Est. completion 19 March 2019
🇦🇺 AU🇨🇦 CA🇨🇿 CZ🇫🇮 FI🇮🇹 IT🇪🇸 ES

**Who might be able to join this trial:** - The child's parent(s) or legal guardian(s) are willing and able to follow the study requirements, such as filling in diary cards and attending follow-up appointments. - The parent(s) or legal guardian(s) have given written permission for their child to take part before any st...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
🇦🇺 NCT02952924 · Hoffmann-La Roche Phase 1 · 8 countries Completed
Completed Phase 1 Est. completion 16 March 2022
🇦🇺 AU🇧🇬 BG🇨🇳 CN Hong Kong🇳🇿 NZ🇸🇬 SG🇹🇼 TW🇹🇭 TH

Who might be able to join this trial: **Part 1 – Healthy volunteers only:** - People with no signs of any active or long-term illness, confirmed through medical history, physical examination, heart tracing (ECG), and blood and urine tests - People with a body weight in the healthy range (BMI between 18 and 30) - Women...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03672188 · Vir Biotechnology, Inc. Phase 2 · 5 countries Completed
Completed Phase 2 Est. completion 3 September 2020
🇦🇺 AU Hong Kong🇳🇿 NZ🇰🇷 KR🇹🇭 TH

**Who might be able to join this trial:** *Part A (Single Dose Study):* - You are a man or woman between 18 and 55 years old - Your body mass index (a measure of body weight relative to height) is between 18 and 32 *Parts B and C (Multiple Dose Study):* - You are a man or woman between 18 and 65 years old - Your body...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04891770 · Gilead Sciences Phase 2 · 8 countries Completed
Completed Phase 2 Est. completion 23 January 2024
🇦🇺 AU🇩🇰 DK Hong Kong🇳🇿 NZ🇸🇬 SG🇰🇷 KR🇹🇭 TH🇬🇧 GB

Who might be able to join this trial: - You are willing and able to give your agreement to take part in the study - You have had a long-term hepatitis B virus (HBV) infection for at least 6 months - You are willing to follow the study's rules about using contraception (birth control) Who may not be able to join: - You...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03038802 · Vaxine Pty Ltd Phase 2 · 1 country Not Yet Recruiting
Not Yet Recruiting Phase 2 Est. completion 1 March 2027
🇦🇺 AU

**Who might be able to join this trial:** - You can be male or female - You must be 18 years of age or older - You must have a current chronic (long-term) Hepatitis B infection, with or without liver scarring (cirrhosis), shown by specific blood test results (note: if you are already on certain Hepatitis B medications,...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04914611 · Kirby Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2030
🇦🇺 AU

Who might be able to join this trial: - People who have been diagnosed with chronic hepatitis B, whether recently or in the past, at one of the participating study locations. - People who are 16 years of age or older. - People who visited the health service for hepatitis B care within the 12 months before the study beg...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT06277037 · Arbutus Biopharma Corporation Not Applicable · 7 countries Recruiting
Recruiting Not Applicable Est. completion 30 August 2029
🇦🇺 AU Hong Kong Moldova🇰🇷 KR🇹🇼 TW🇬🇧 GB🇺🇸 US

"Who might be able to join this trial: - You must have already taken part in a previous clinical trial involving a drug called imdusiran. - You must have stopped taking a type of antiviral medication (called nucleoside analogue or NA therapy) during that previous trial, and still be off that medication. - You must have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT07024641 · GigaGen, Inc. Phase 1 · 5 countries Recruiting
Recruiting Phase 1 Est. completion 1 November 2028
🇦🇺 AU Hong Kong🇰🇷 KR🇹🇼 TW🇺🇸 US

**Who might be able to join this trial:** - People who have had chronic Hepatitis B infection (specifically the "HBeAg negative" type) for at least 6 months, confirmed by a protein called HBsAg being present in the blood for that time. - People whose blood shows a specific level of the HBsAg protein — at least 100 but...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07059403 · Chimivac INC Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 April 2027
🇦🇺 AU

**Who might be able to join this trial:** - People aged between 18 and 55 years old (inclusive) - People with a body mass index (BMI) between 18.0 and 32.0 (a measure of body weight relative to height) - People who a doctor has assessed to be in good general health, based on medical history, physical checks, heart tra...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07370207 · AusperBio Therapeutics Inc. Phase 2 · 6 countries Recruiting
Recruiting Phase 2 Est. completion 31 December 2028
🇦🇺 AU🇨🇳 CN🇳🇿 NZ🇸🇬 SG🇰🇷 KR🇹🇼 TW

Who might be able to join this trial: - Adults aged 18 to 65 years old who are able to give informed consent, follow study procedures, and agree to stop their hepatitis B antiviral tablet medication if certain conditions set out in the study protocol are met. - People with a body mass index (a measure of body weight re...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02577029 · Arrowhead Pharmaceuticals Phase 2 · 8 countries Terminated
Terminated Phase 2 Est. completion 1 December 2016
🇦🇺 AU🇧🇬 BG🇨🇳 CN Moldova🇳🇿 NZ🇰🇷 KR🇹🇼 TW🇹🇭 TH

Who might be able to join this trial: - You are between 18 and 75 years old (male or female) - You are willing and able to provide written consent to participate - Your heart tracing test (ECG) at the screening visit shows no significant problems - You have been diagnosed with a long-term (chronic) hepatitis B virus (H...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04465916 · Enyo Pharma Phase 2 · 4 countries Terminated
Terminated Phase 2 Est. completion 17 June 2021
🇦🇺 AU Hong Kong🇵🇱 PL🇰🇷 KR

**Who might be able to join this trial:** - You have been taking a stable hepatitis B antiviral medication (either entecavir or tenofovir disoproxil fumarate) for at least 12 months before the study screening date. - Your hepatitis B virus is well controlled by your medication — meaning the virus is at an undetectable...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00404989 · Syneos Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2099
🇺🇸 US

**Who might be able to join this trial:** - People of childbearing potential who took the registry medication during pregnancy - Cases where the country where the report originates can be documented - Cases where there is clear documentation that the registry drug was taken during pregnancy - Cases where it can be det...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02883647 · Third Affiliated Hospital, Sun Yat-Sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2024
🇨🇳 CN

Who might be able to join this trial: - People who have been receiving antiviral treatment for hepatitis B (a type of medication called nucleoside/nucleotide analogs). - People whose antiviral treatment has been ongoing for at least 2 years. - People who had a specific hepatitis B protein (HBeAg) detected in their bloo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03097952 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medic... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2030
🇨🇳 CN

Who might be able to join this trial: - People who have had a chronic hepatitis B infection, meaning they have tested positive for the hepatitis B surface antigen (HBsAg) for at least 6 months. Who may not be able to join: - People who are also infected with HIV, hepatitis C, or hepatitis D. - People who have previous...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03792919 · Humanity & Health Medical Group Limited Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2025
Hong Kong

Who might be able to join this trial: - People who have tested positive for a specific hepatitis B surface marker (HBsAg), negative for another hepatitis B marker (HBeAg), and positive for the antibody related to that second marker - People who have been on a single antiviral medication for hepatitis B continuously for...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT03825458 · Hospices Civils de Lyon Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 25 June 2029
🇫🇷 FR🇮🇹 IT

Who might be able to join this trial: - Adults and children over 6 years of age (in Lyon) who have acute or chronic hepatitis B, or who have experienced loss of a marker called HBsAg (with or without a related antibody response) - People who are also co-infected with other viruses such as HDV, HCV, or HIV may still be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03826433 · Sclnow Biotechnology Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 60 years old, of any gender, with a body mass index (BMI) between 19 and 25 (a measure of body weight relative to height). - People diagnosed with liver scarring (cirrhosis) caused by hepatitis B, with liver function rated as Child-Pugh B or Child-Pugh C wi...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03920618 · Third Affiliated Hospital, Sun Yat-Sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2024
🇨🇳 CN

Who might be able to join this trial: - People who have tested positive for hepatitis B surface antigen, or have had detectable hepatitis B virus in their blood, for more than 6 months - People aged between 12 and 65 years old - People whose blood test shows a bilirubin level (a measure of liver stress) more than 10 ti...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03933384 · Taichung Veterans General Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2027
🇹🇼 TW

Who might be able to join this trial: - You are older than 20 years of age - You have been diagnosed with chronic hepatitis B - Your doctor has recommended that you start antiviral treatment for hepatitis B Who may not be able to join: - Your liver disease is at an advanced stage where the liver is no longer functioni...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT04139850 · Yonsei University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇰🇷 KR

Who might be able to join this trial: - People who are 20 years of age or older (above 19 years). - People who have been diagnosed with chronic hepatitis B, with a positive HBsAg test result lasting more than 6 months. - People who are already receiving regular check-ups or monitoring for chronic hepatitis B at a medic...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04166266 · ANRS, Emerging Infectious Diseases Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇫🇷 FR

Who might be able to join this trial: - You must be over 18 years old - You must have a long-term (chronic) infection with Hepatitis D virus (HDV), confirmed by a positive blood test - You must be willing to sign a consent form agreeing to take part before joining the trial - You must be covered by health insurance or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04231565 · Third Affiliated Hospital, Sun Yat-Sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2024
🇨🇳 CN

**Who might be able to join this trial:** - You have tested positive for hepatitis B (both the surface antigen and hepatitis B antibody) for more than 6 months - You are between 18 and 65 years old - Your liver enzyme levels (a blood test measure called ALT) have been within the normal range for at least 12 weeks - You...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04310787 · Third Affiliated Hospital, Sun Yat-Sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2024
🇨🇳 CN

Who might be able to join this trial: - People who are between 18 and 65 years old - People who have been diagnosed with acute-on-chronic liver failure related to hepatitis B - People who survived for more than 90 days after being admitted to hospital - People whose medical records from their hospital stay are complete...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04588077 · Mercy Medical Center Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 December 2028
🇺🇸 US

Who might be able to join this trial: - People over 18 years old who have liver cirrhosis and attended the hepatology clinic at Mercy Medical Center between September 2020 and July 2021 - People who do not have sufficient protection against Hepatitis B, based on a blood test result showing an anti-HBs level below 10 mI...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT04597164 · Third Affiliated Hospital, Sun Yat-Sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with a long-term hepatitis B infection, shown by a positive test result lasting more than 6 months - People aged between 18 and 65 years old - People who have been diagnosed with liver failure, based on specific blood test results showing the l...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04745403 · Lion TCR Pte. Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 July 2026
🇸🇬 SG

**Who might be able to join this trial:** - People who are generally well enough to carry out light activity and care for themselves, with little or no restriction on daily activities (measured by a standard medical scale called ECOG, with a score of 0 or 1) - People who have been diagnosed with liver cancer (hepatoce...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04843852 · University of Maryland, Baltimore Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 October 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are over 18 years old - People who have been diagnosed with chronic hepatitis B infection (meaning a positive hepatitis B test result for at least 6 months), without also having HIV, hepatitis C, or hepatitis D - People who have been taking antiviral medication fo...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04896255 · Huashan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older, where those over 70 years old need to be in generally stable health overall. - People who have had a positive HBsAg test result (a marker for hepatitis B) for more than 6 months, or who have liver tissue changes related to hepatitis B infection. - Pe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04970836 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇹🇼 TW

**Who might be able to join this trial:** - You are over 20 years old and were born after 1987 - You were born in Taiwan and received at least 3 doses of the hepatitis B vaccine as a baby - Your blood test shows no signs of current or past hepatitis B infection (both surface antibody and surface antigen tests came back...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05051098 · Hannover Medical School Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇩🇪 DE

**Who might be able to join this trial:** - You have been diagnosed with a Hepatitis B virus infection - You have tested positive for a specific Hepatitis B marker (called HBsAg) for at least 1 year before joining the trial - Your Hepatitis B "e-antigen" (HBeAg) status has been monitored and documented for at least 6 m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05182463 · Third Affiliated Hospital, Sun Yat-Sen University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 13 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 60 years old, any gender - People who have tested positive for the hepatitis B surface antigen (a marker of hepatitis B infection) for more than 6 months - People whose hepatitis B blood test results show a specific pattern: negative for HBeAg and positive f...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05195450 · Institute of Liver and Biliary Sciences, India Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇮🇳 IN

**Who might be able to join this trial:** - People who test positive for the hepatitis B surface antigen (a marker showing hepatitis B is present in the body) - People whose liver enzyme levels (ALT) have stayed within the normal range over two separate tests, taken 3 to 6 months apart — normal is below 30 IU/ml for ma...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05361603 · University Hospital, Limoges Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 9 December 2022
🇫🇷 FR

Who might be able to join this trial: - You must be 18 years old or older - You either visit an alternative or community-based care setting (outside of a traditional hospital or clinic), or you have been referred by a healthcare professional - You have agreed to take part in the research study Who may not be able to j...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05390424 · University Hospital, Rouen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇫🇷 FR

Who might be able to join this trial: - You currently use or have previously used drugs by injection or by snorting through the nose - You are currently on a prescribed medication programme to help manage opioid (e.g. heroin) dependence, such as methadone or buprenorphine Who may not be able to join: - You have a know...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05392387 · Xiangya Hospital of Central South University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 October 2024
🇨🇳 CN

**Who might be able to join this trial:** - People who have a long-term (chronic) hepatitis B virus (HBV) infection, shown through medical evidence **Who may not be able to join:** - People whose long-term liver damage is mainly caused by something other than hepatitis B, such as autoimmune diseases, alcohol use, or c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05403047 · ANRS, Emerging Infectious Diseases Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 August 2027
Cameroon

**Who might be able to join this trial:** - Pregnant women who are less than 24 weeks into their pregnancy - People who test positive for HBsAg (a marker showing hepatitis B is present in the blood) - People who test positive for HBeAg (another hepatitis B marker), or who test negative for HBeAg but have a high level o...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05417932 · SCG Cell Therapy Pte. Ltd. Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 1 September 2025
Hong Kong🇸🇬 SG🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with liver cancer (hepatocellular carcinoma) confirmed by a laboratory test on a tissue or cell sample - You have already tried at least 2 standard treatments for your liver cancer - You have a specific genetic marker called HLA-A\*02 (a blood test ca...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05466565 · Xiangya Hospital of Central South University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 65 years old (any gender) - You have been diagnosed with liver cancer (hepatocellular carcinoma) and have had it treated with surgery to remove the tumour or a procedure called radiofrequency ablation (which uses heat to destroy the tumour) - You test p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05583006 · Taichung Veterans General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇹🇼 TW

**Who might be able to join this trial:** - People who are at least 20 years old - People who have a detectable level of a hepatitis B protein (HBsAg) in their blood - People who have a long-term hepatitis B virus (HBV) infection and are currently being treated with a medication called entecavir (ETV) - People who are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05661786 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medic... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have tested positive for the hepatitis B surface antigen (a marker of hepatitis B infection) for more than 6 months - People who are 18 years of age or older - People who have never previously been treated for hepatitis B - People whose hepatitis B is in a specific...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05686759 · GC Biopharma Corp Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 June 2026
🇰🇷 KR

**Who might be able to join this trial:** - People aged 18 to 64 years old at the time of signing the consent form - People who have had a liver transplant because of serious liver disease caused by hepatitis B, such as severe scarring of the liver (cirrhosis), liver cancer, or sudden liver failure, and who have been r...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05769816 · The Second Affiliated Hospital of Chongqing Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are willing and able to sign a consent form and follow the study requirements throughout the trial - You are willing to use effective birth control from the time you join until 30 days after your last dose of the study drug (applies to men and women who could become pregn...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05771402 · The Second Affiliated Hospital of Chongqing Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are willing and able to sign a consent form and follow all study requirements throughout the trial - You are willing to use effective birth control from the time you join until 30 days after your last dose of the study drug (applies to men and women who could become pregn...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05853718 · First People's Hospital of Hangzhou Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are between 20 and 40 years old - You have tested positive for hepatitis B (specifically for two markers called HBsAg and HBeAg) - Your hepatitis B virus levels in the blood are above a certain high level (200,000 IU/mL) between weeks 24 and 32 of your pregnancy - You are...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05856890 · Rockefeller University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2027
🇺🇸 US

Who might be able to join this trial: - People aged between 18 and 70 years old - People who have had a confirmed hepatitis B (HBV) infection for at least 6 months, shown by a positive HBsAg test - People who have been taking an antiviral medication for hepatitis B for at least 6 months, with no change to that medicati...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05905172 · Beijing Continent Pharmaceutical Co, Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 20 June 2028
🇨🇳 CN

**Who might be able to join this trial:** - You must have already taken part in the related Phase III trial (NCT05115942), completed the full treatment course, and attended the final visit. - You must be willing to take part voluntarily, be able to communicate well with the research team, follow all study requirements,...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05922306 · Anhui Medical University Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 60 years old (including both ages), of any sex - You have tested positive for the hepatitis B surface antigen (a marker of hepatitis B infection) for more than 6 months - If you are already on antiviral medication for hepatitis B: you have been taking i...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT05936073 · University Hospital, Limoges Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 22 June 2025
🇫🇷 FR

**Who might be able to join this trial:** - People who are over 18 years of age at the second step of the study - People who have tested positive for HDV RNA (a marker for Hepatitis Delta virus infection) at the second step of the study - People who have not objected to having their data collected for this study **Who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05937178 · Huashan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2029
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with chronic hepatitis B, meaning you have tested positive for the hepatitis B surface antigen for at least 6 months, or have liver biopsy results showing hepatitis B-related changes within the past year - You are between 18 and 80 years old - You are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05977283 · Nanfang Hospital, Southern Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - Your hepatitis B surface antigen (HBsAg) blood levels must have dropped by a certain amount over the past 12 months before screening — this can be due to any reason, whether or not you have been on newer treatments (confirm with trial site for exact level required). - You mus...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06023056 · Children's Hospital of Chongqing Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2030
🇨🇳 CN

Who might be able to join this trial: - Babies born at full term (not premature) - Babies who have had staged surgery on their digestive system (surgeries done in separate steps) - Babies who have tested negative for hepatitis B surface antigen (a marker for hepatitis B infection) - Babies who do not have a disease aff...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06047093 · Hospices Civils de Lyon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 8 March 2030
🇫🇷 FR

**Who might be able to join this trial:** - Adults aged 18 or older - People who have a long-term (chronic) hepatitis B virus infection, at any stage - People who are currently taking antiviral medication for hepatitis B (called nucleoside analogues), or those who are not on any treatment - People who also have a hepat...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06082336 · MagIA Diagnostics Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 26 August 2025
🇫🇷 FR

Who might be able to join this trial: - Adults aged 18 years or older - People who are known to have HIV infection, known to have hepatitis B (HBV) infection, or known or suspected to have hepatitis C (HCV) infection with a positive rapid test result - People who have agreed and given consent to take part in the study...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06084234 · University of Texas Southwestern Medical Center Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2029
🇺🇸 US

**Who might be able to join this trial:** - Adults between 18 and 85 years old who have cirrhosis (scarring of the liver) from any cause, or who have chronic hepatitis B with a liver cancer risk score (called PAGE-B) above 9, measured within the past 12 months - People whose treating doctor or the trial site considers...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06092333 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDD... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 29 February 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 65 years - People who test positive for a specific hepatitis B surface protein (HBsAg) at a low level (below 2,000 IU/mL) at the time of screening - People who test negative for hepatitis B e antigen, which is a marker related to how active the hepatitis B...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06154278 · University of Maryland, Baltimore Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older at the time of screening - People who are in good general health based on their medical history - People who have been diagnosed with chronic hepatitis B infection, meaning a specific protein called HBsAg has been detected in their blood at screening...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06160635 · Hannover Medical School Not Applicable · 4 countries Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇩🇪 DE🇮🇹 IT🇷🇴 RO🇸🇪 SE

Who might be able to join this trial: - People who have tested positive for anti-HDV (an antibody related to the Hepatitis Delta virus) - People aged 18 years or older - People of any gender (male, female, or diverse) - People who have given their informed consent to take part in the study's procedures Who may not be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06216470 · University Health Network, Toronto Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2029
🇨🇦 CA

**Who might be able to join this trial:** - You are between 18 and 65 years old - You have had a chronic Hepatitis B infection (confirmed by a positive HBsAg blood test for more than 6 months) - Your Hepatitis B surface antigen (HBsAg) level falls within a specific range (300–10,000 IU/mL) on a blood test - You have be...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06263959 · Fujian Akeylink Biotechnology Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2025
🇨🇳 CN

Who might be able to join this trial: - People aged 35 to 65 years old (men or women) who are able to follow the study plan and communicate well with the research team - People who are willing and able to sign a consent form after being fully informed about the study, including its content, steps, and possible side eff...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06295328 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2025
🇳🇱 NL

Who might be able to join this trial: - You are between 18 and 60 years old - You have been diagnosed with chronic hepatitis B (a long-term liver infection) for more than 6 months, confirmed by blood tests, and your virus levels fall into one of two specific ranges (the trial team will check which group you belong to)...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06323681 · Qing XIe Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part voluntarily and are able to understand and sign a consent form. - People aged between 18 and 65 years old (inclusive). - People who have tested positive for the hepatitis B surface antigen (HBsAg) for at least 6 months, or have other evide...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06364930 · Chinese University of Hong Kong Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 October 2030
Hong Kong

**Who might be able to join this trial:** - You have chronic hepatitis B and have been taking one of these antiviral medications (entecavir, tenofovir disoproxil fumarate, or tenofovir alafenamide) on its own for at least 12 months - You have been diagnosed with type 2 diabetes, or have blood sugar levels high enough t...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06425341 · Fujian Shengdi Pharmaceutical Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - People with a body mass index (a measure of body weight relative to height) between 18.5 and below 35 - People who have had a chronic hepatitis B infection documented for at least 6 months before the screening visit - People whose hepatitis B virus levels in the blood are cu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06513286 · Michael Hoelscher Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇩🇪 DE

**Who might be able to join this trial:** - People who are able to understand the trial information and are willing to sign a consent form agreeing to take part. - People who have had a confirmed chronic Hepatitis B virus (HBV) infection for at least 6 months, with specific blood test results showing HBsAg levels betw...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06525909 · Tongji Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 50 years old who have had a positive HBsAg blood test result (a marker for hepatitis B) for more than 6 months, indicating chronic hepatitis B (CHB) - People in the untreated group whose condition fits one of the four recognised stages of chronic h...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06544863 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 19 March 2040
🇫🇷 FR

Who might be able to join this trial: - People who are 18 years of age or older - People who are being treated or monitored for cirrhosis, suspected cirrhosis, or a condition called hepatic tumour (TH) at Pitié Salpêtrière University Hospital - People who have been informed about the study and have signed a consent for...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06550622 · Huashan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 August 2027
🇨🇳 CN

**Who might be able to join this trial:** - Your blood test shows that a specific hepatitis B protein (HBsAg) is no longer detectable, and another hepatitis B marker (HBeAg) is also not detectable - You have blood samples that were stored both at the start of a previous treatment and at 48 weeks after that treatment en...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06586983 · Oslo University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 5 September 2028
Ethiopia

Who might be able to join this trial: - You are 18 years of age or older - You have tested positive for HBsAg (a marker in your blood that indicates a hepatitis B infection) Who may not be able to join: - You are under 18 years of age - Your HBsAg rapid test came back negative at the first screening appointment (meani...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06617000 · SCG Cell Therapy Pte. Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2025
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with liver cancer (hepatocellular carcinoma) confirmed by a laboratory test on a tissue or cell sample. - You have already received standard treatments for your liver cancer. - You have a specific immune system marker called HLA-A\*02 (this is a genetic ch...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06623071 · CerbaXpert Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 24 March 2025
🇫🇷 FR

**Who might be able to join this trial:** - You must be 18 years of age or older - You must be visiting the study centre and either have a doctor's request to test your Hepatitis B virus (HBV) levels, or have already been confirmed to have an HBV infection using an approved test - You must be able to understand what th...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06638320 · Tam Anh Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2026
🇻🇳 VN

Who might be able to join this trial: - You are 16 years old or older and have had a positive hepatitis B surface antigen (HBsAg) test for six months or more, or have specific related test results showing long-term hepatitis B infection, and are getting tested at Tam Anh General Hospital (Hanoi or Ho Chi Minh City) - Y...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06650852 · Brii Biosciences Limited Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are male or female, aged between 18 and 60 years old - People with a body mass index (a measure of body weight relative to height) between 18 and 32 - People who have had a chronic hepatitis B virus (HBV) infection for at least 6 months - People who have been takin...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06658782 · University of Oxford Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2029
🇬🇧 GB

**Who might be able to join this trial:** - You are willing and able to give your consent to take part in the study - You are 18 years old or older, of any gender - Your doctor thinks you are suitable for routine liver cancer screening using ultrasound - Your liver is functioning at a level rated as Child-Pugh A or B...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06668727 · Aarhus University Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 26 August 2027
🇩🇰 DK

**Who might be able to join this trial:** - Adults aged 18 to 70 years old - People who have had a confirmed hepatitis B (HBV) infection for at least 6 months, shown by a positive HBsAg blood test - People who have been taking an approved hepatitis B antiviral medication for at least 6 months, with no change to that m...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06671093 · Tune Therapeutics, Inc. Phase 1 · 3 countries Recruiting
Recruiting Phase 1 Est. completion 28 June 2028
Hong Kong Moldova🇳🇿 NZ

Who might be able to join this trial: - You are male or female, between 18 and 75 years old (inclusive) - Your body weight is in a healthy or higher range (BMI of 18.5 or above) at the time of screening - You have been diagnosed with Chronic Hepatitis B - You are currently taking antiviral medication known as a nucleos...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06680232 · Precision BioSciences, Inc. Phase 1 · 4 countries Recruiting
Recruiting Phase 1 Est. completion 1 December 2025
Hong Kong Moldova🇳🇿 NZ🇺🇸 US

**Who might be able to join this trial:** - People who are male, or female and not able to become pregnant - People with a Body Mass Index (a measure of body weight relative to height) between 18.0 and 35.0 - People who are in good overall health, as assessed by the trial doctor - People who have had a confirmed chroni...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06696664 · Minghui Li Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 70 years old, of Han ethnicity, and any gender may apply - You have been diagnosed with chronic hepatitis B (CHB), meaning you have tested positive for the hepatitis B virus for more than 6 months and have ongoing liver inflammation caused by the virus...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06746701 · Xiangya Hospital of Central South University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 May 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 65 years (any gender) - People who have tested positive for the hepatitis B surface antigen (a marker of hepatitis B infection) for at least 6 months - People who have a family history of liver cancer, meaning at least one close or extended family member (s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06755632 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 19 June 2027
🇫🇷 FR

Who might be able to join this trial: - You must be 18 years old or older - You must be willing and able to sign a consent form to take part - You must be covered by a Social Security system (confirm with trial site) Who may not be able to join: - You cannot take part if you are currently pregnant or breastfeeding - Y...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06779058 · Shengjing Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇳 CN

Who might be able to join this trial: - You must be 18 years old or older - You must have a confirmed diagnosis of chronic hepatitis B, confirmed through blood tests, imaging, and clinical examination - You must have had a specific liver imaging scan called MRE (magnetic resonance elastography) within 6 months before o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06779864 · Beijing Friendship Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2025
🇨🇳 CN

Who might be able to join this trial: - People who have tested positive for hepatitis B surface antigen (a marker in the blood that shows hepatitis B infection) - People who have complete personal and medical information on file, along with stored blood samples or liver tissue samples Who may not be able to join: - Pe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06803368 · Beijing Municipal Administration of Hospitals Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 October 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 65 years old - You are any gender - You have been diagnosed with chronic Hepatitis B (a long-term liver infection caused by the Hepatitis B virus), based on 2019 medical guidelines - Your Hepatitis B was treated with interferon, and that treatment cause...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06834178 · Vanessa Stadlbauer-Koellner, MD Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇦🇹 AT

Who might be able to join this trial: - People with hepatitis C (HCV) who have a detectable level of the hepatitis C virus in their blood at their most recent test - People with hepatitis B (HBV) who have had a detectable level of the hepatitis B virus in their blood at any point, and who have either never been tested...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06853886 · University Hospital, Limoges Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2028
🇫🇷 FR

Who might be able to join this trial: - Adults aged 18 or older who have a hepatitis B virus (HBV) infection, whether it is untreated or being treated with a certain type of antiviral medication - People who are willing and able to sign a written consent form agreeing to take part - People who are covered by a social s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06874127 · Beijing Friendship Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2026
🇨🇳 CN

**Who might be able to join this trial:** - You had a liver tissue sample (biopsy) taken at least 1 year after completing antiviral treatment - You had a liver biopsy, a liver stiffness test, or a specific blood test (called APRI, which measures liver health using two markers in your blood) done *before* starting antiv...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06876467 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 11 December 2028
🇫🇷 FR

Who might be able to join this trial: - You must be 18 years old or older - You must have had a blood test to check your hepatitis B status done within 4 weeks before receiving the vaccination - You must have agreed to take part (given your consent/no objection to participation) Who may not be able to join: - People w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06881238 · Tanta University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 May 2025
🇪🇬 EG

Who might be able to join this trial: - Adults aged 18 years or older (both male and female) - People who have been diagnosed with Inflammatory Bowel Disease (IBD) — a condition affecting the digestive system — confirmed through a combination of clinical assessment, imaging scans, camera examination of the gut, and tis...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06885710 · Changhai Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with chronic Hepatitis B infection, shown by a positive HBsAg blood test for at least 6 months - Your blood test for a marker called HBeAg can be either positive or negative — both are accepted - Your genetic tissue type (called HLA type) matches one o...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06887036 · Fondazione Epatocentro Ticino Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 October 2026
🇨🇭 CH

Who might be able to join this trial: - People who have given their signed agreement to take part in the study - People aged 18 or older but under 80 years old - People who have a confirmed long-term (chronic) Hepatitis B virus (HBV) infection, sometimes called being an "inactive HBV carrier" - People whose Hepatitis B...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06904820 · University Hospital, Limoges Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 5 June 2035
🇫🇷 FR

Who might be able to join this trial: - Adults aged 18 or older - People who regularly visit an unconventional "outside the walls" care setting, or who have been referred by a healthcare professional - People who do not object to taking part in research Who may not be able to join: - People under the age of 18 - Peopl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06906016 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 27 November 2038
🇫🇷 FR

Who might be able to join this trial: - You are at least 18 years old - You have a long-term hepatitis B infection, meaning you have tested positive for the hepatitis B surface antigen (HBsAg) for more than 6 months - You are currently receiving care at the Henri Mondor-Albert Chenevier University Hospital group Who m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06947356 · Guangzhou 8th People's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2028
🇨🇳 CN

**Who might be able to join this trial:** - You are a pregnant woman between 20 and 40 years old - Your pregnancy is between 20 and 28 weeks along - You have been diagnosed with chronic hepatitis B that is considered "compensated" (meaning your liver is still functioning), and you have tested positive for the hepatitis...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06947499 · LG Chem Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 November 2026
🇵🇭 PH

**Who might be able to join this trial:** - Healthy babies who are between 6 and 8 weeks old (both ages included) - Babies who weigh at least 3.2 kg (about 7 pounds) - Babies who were born after a full-term pregnancy (at least 37 weeks) - A parent or legal guardian has signed the consent forms to allow the baby to take...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06963710 · Aligos Therapeutics Phase 2 · 14 countries Recruiting
Recruiting Phase 2 Est. completion 1 March 2027
🇧🇬 BG🇨🇦 CA🇨🇳 CN🇫🇷 FR Hong Kong🇮🇹 IT Moldova🇳🇿 NZ +6 more

**Who might be able to join this trial:** - People aged 18 to 65 years old (or the minimum age required by local regulations) with a body mass index (BMI) between 18.0 and 35.0 — a standard measure of body weight relative to height. - People who have a specific type of hepatitis B virus (HBV) marker in their blood cal...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06966232 · Sun Yat-sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 15 May 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old - You have been diagnosed with an advanced or spreading cancer of the digestive system (such as colorectal, stomach, esophageal, liver, pancreatic, or bile duct cancer) that cannot be surgically removed, confirmed by a tissue biopsy - You...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06966908 · Third Affiliated Hospital, Sun Yat-Sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who test positive for hepatitis B (HBsAg-positive) and are currently being seen in departments *other than* infectious disease or hepatology clinics at one of the three study centres. *The following criteria apply to a specific part of the trial called the PRO sub-st...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07051187 · Jiyan Liu Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 September 2027
🇨🇳 CN

Who might be able to join this trial: - Adults between 18 and 65 years old (inclusive) - People with a body mass index (a measure of body weight relative to height) between 18 and 32 - People who have been diagnosed with chronic hepatitis B infection, meaning a specific protein marker (HBsAg) has been present in their...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07069569 · Ausper Biopharma Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 July 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part voluntarily and able to follow the study schedule as required - You are between 18 and 65 years old at the time of signing the consent form - Your body weight is in a healthy range for your height (BMI between 18 and 30) - A specific hepatitis B...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07079150 · First Affiliated Hospital Xi'an Jiaotong University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2032
🇨🇳 CN

**Who might be able to join this trial:** - People who come from a family where hepatitis B virus (HBV) infection has occurred across two generations of blood relatives, and where at least one person in two or more generations has developed cirrhosis (liver scarring) or liver cancer linked to HBV - People who have bee...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07090759 · Fujian Akeylink Biotechnology Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 70 years old (men or women) - Men weighing at least 50 kg, or women weighing at least 45 kg, with a body mass index (BMI) between 18 and 35 - People who have been continuously taking one of the following hepatitis B antiviral medicines for more than one yea...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07137247 · Nanfang Hospital, Southern Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2040
🇨🇳 CN

Who might be able to join this trial: - People aged between 1 and 80 years old, male or female - People who have been diagnosed with chronic hepatitis B virus infection, based on the 2019 Chinese guidelines for the prevention and treatment of chronic hepatitis B - People who have not received any antiviral treatments (...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07137910 · Ausper Biopharma Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 12 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part voluntarily and sign a consent form - People aged 18 to 65 years old (including those who are exactly 18 or 65) - People whose body weight relative to their height falls within the range required by the trial - People who have had chronic h...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07146100 · Ausper Biopharma Co., Ltd. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2028
🇨🇳 CN

**Who might be able to join this trial:** - You must be able to understand and agree to participate by giving your informed consent. - You must have previously taken part in a related study where you received at least one dose of AHB-137, your condition fully or partially improved without needing any rescue medication,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07170748 · MagIA Diagnostics Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
Côte d’Ivoire Kenya

Who might be able to join this trial: - You must be willing and able to give your agreement (consent) to take part in the study - You may be eligible if you have a blood sample (serum or plasma) that tests positive for HIV-1 antibodies, HIV-2 antibodies, Hepatitis C antibodies, Hepatitis B surface antigen, or syphilis...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07179575 · Shanghai Longwood Biopharmaceuticals Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2027
🇨🇳 CN

**Who might be able to join this trial:** - **Part 1 (people not currently on treatment):** People with hepatitis B who have never been treated or are not currently being treated, where their hepatitis B virus levels in the blood and a protein produced by the virus (called HBsAg) both fall within specific ranges set b...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07189377 · University Health Network, Toronto Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 August 2027
🇨🇦 CA

**Who might be able to join this trial:** *(For organ donors:)* - The donated lungs must be considered suitable for transplantation - The donor must have tested positive for Hepatitis B (either through a surface antigen test or a nucleic acid test) *(For recipients — the person receiving the lung):* - You must alread...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07198854 · Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with a condition where a long-term liver disease has suddenly gotten much worse (known as acute-on-chronic liver failure) - You have tested positive for the hepatitis B virus (HBV) surface antigen in your blood for more than 6 months, meaning you have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07200193 · nChroma Bio Phase 2 · 4 countries Recruiting
Recruiting Phase 2 Est. completion 31 December 2032
🇫🇷 FR Hong Kong🇳🇿 NZ🇬🇧 GB

Who might be able to join this trial: - People aged 18 to 64 years old, weighing between 45 and 150 kg, of any gender - People who have been diagnosed with Chronic Hepatitis B - People who are currently taking oral antiviral medication for their condition - People whose liver enzyme levels (ALT and AST) are within an a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07240350 · Nanfang Hospital, Southern Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are a man or woman who has been diagnosed with chronic hepatitis B, or you have tested negative for hepatitis B surface antigen but have a related clinical diagnosis, and you are scheduled to have surgery on your liver, spleen, tonsils, or lymph nodes. - You have read and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07257562 · First Affiliated Hospital of Fujian Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with chronic hepatitis B Who may not be able to join: - People who have been diagnosed with cancer or any type of malignant tumour - People who have been diagnosed with other liver diseases (separate from hepatitis B) - People who are currently pre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07275554 · Qilu Hospital of Shandong University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have had a positive hepatitis B surface antigen (a blood marker showing hepatitis B infection) for more than six months, which indicates a long-term hepatitis B infection - People who have been diagnosed with liver scarring (cirrhosis) caused by hepatitis B, confi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07275918 · Suzhou Siran Biotechnology Co.,Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 March 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are able to read, understand, and sign a written consent form. - Men or women aged 18–55 years old (for healthy participants) or 18–65 years old (for those with chronic hepatitis B). - People whose Body Mass Index (BMI) falls within 18–28 kg/m² (for healthy partic...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07307586 · Zhigang Ren Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with chronic hepatitis B according to specific Chinese medical guidelines, and who have tested positive for two hepatitis B markers (called HBeAg and HBsAg) for at least six months continuously - People whose hepatitis B virus levels in the blo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07328711 · Peking University People's Hospital Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - People between 18 and 60 years old (inclusive) - People who have tested positive for hepatitis B (via HBsAg and/or HBV DNA blood tests) for more than 6 months - People whose hepatitis B surface antigen (HBsAg) has dropped to an undetectable level after completing a treatment...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07342881 · Aligos Therapeutics Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 15 June 2026
🇺🇸 US

Who might be able to join this trial: - You are a man or woman between 18 and 75 years old - Your body mass index (a measure of body weight relative to height) is between 17.5 and 40.0, and you weigh more than 50 kg (110 lbs) - If you are a woman who could become pregnant, you and any male partner who has not had a vas...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07343778 · Beijing Continent Pharmaceutical Co, Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 October 2026
🇨🇳 CN

**Who might be able to join this trial:** - You fully understand the study, are joining voluntarily, and have signed the consent form. - You are 18 years old or older, any gender. - You have a confirmed diagnosis of liver scarring (fibrosis) or advanced liver scarring (cirrhosis), shown either by a liver biopsy taken w...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07364448 · Beijing Continent Pharmaceutical Co, Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years old or older, of any gender. - You have been assessed by a doctor as having chronic hepatitis B with liver scarring (fibrosis), OR fatty liver disease with fibrosis, including early-stage cirrhosis that is still "compensated" (meaning the liver is still func...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07389044 · IntegerBio Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 30 April 2027
Moldova🇳🇿 NZ

**Who might be able to join this trial:** This trial has two parts. Part A is for healthy volunteers, and Part B is for people with chronic hepatitis B. **Part A – Healthy Volunteers** Who might be able to join this trial: - People aged 18 to 70 years, male or female, who are able and willing to sign a consent form...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07413549 · Beijing Tuohua Weiye Biotechnology Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old at the time of screening, of any gender. - People who have been diagnosed with decompensated hepatitis B cirrhosis with a history of complications related to high blood pressure in the liver's portal vein, based on specific 2019 Chines...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07417553 · Beijing Continent Pharmaceutical Co, Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 70 years old (inclusive), of any gender, based on their age at the time of signing the consent form. - People who have had chronic hepatitis B for 6 months or longer, or who have tested positive for the hepatitis B surface antigen (HBsAg) for at least 6 mon...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07449091 · NYU Langone Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 to 64 years who have a long-term (chronic) hepatitis B infection, falling into one of three groups: - Group 1 – People with hepatitis B who have been taking antiviral medication (TAF or TDF) for at least 2 years and whose virus levels have been consistently kept v...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07491848 · Research Center of Periodontal-Systemic Interactions Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 February 2027
🇷🇴 RO

Who might be able to join this trial: - Adults aged 18 or older who are able to give their informed consent to participate - People in the Hepatitis B+D groups: those who have been confirmed to have both a hepatitis B and hepatitis D infection at the same time - People in the Bulevirtide group: those who are currently...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07511218 · Ausper Biopharma Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 December 2027
🇨🇳 CN

**Who might be able to join this trial:** *For healthy participants:* - Men or women between 18 and 55 years old. - Body weight in a healthy range, with a BMI between 18.0 and 28.0 (confirm with trial site for exact measurement). - Routine health checks done during screening — including blood tests, heart tracing (ECG...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07519330 · Huahui Health Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 28 February 2028
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 to 45 years old (male or female). - Men weighing at least 50 kg, or women weighing at least 45 kg, with a body mass index (BMI) between 18 and 28. - People who have had a positive hepatitis B surface antigen (HBsAg) and/or detectable hepatitis B virus in the blood...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07540637 · Institute of Gastroenterology and Hepatology, Vietnam Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2026
🇻🇳 VN

Who might be able to join this trial: - You are 18 years old or older. - You have been diagnosed with Chronic Hepatitis B, meaning a specific protein (HBsAg) or the hepatitis B virus has been detected in your blood for 6 months or more, or you have had a positive HBsAg test with a negative IgM antibody result (confirm...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07563309 · bioLytical Laboratories Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇿🇦 ZA

**Who might be able to join this trial:** - You are 18 years of age or older - You are willing and able to sign and date a consent form agreeing to take part - You are able to complete the required tests on the day you are scheduled for testing - You can speak, read, and write English, or a translator can be available...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07573943 · The Second Affiliated Hospital of Chongqing Medical University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2026
🇨🇳 CN

Who might be able to join this trial: - Your body mass index (BMI) must be between 18 and 32 (a measure of weight relative to height) - Your blood must show a low level of a hepatitis B protein called HBsAg (below 100 IU/mL, as measured by a blood test) - The amount of hepatitis B virus in your blood must be very low o...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07610772 · Aarhus University Hospital Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 1 April 2028
🇩🇰 DK🇩🇪 DE

**Who might be able to join this trial:** - You have been confirmed to have HDV (Hepatitis Delta Virus) infection through blood tests showing both HDV antibodies and detectable HDV in your blood - You do not have Hepatitis B surface antibodies showing up in recent blood tests - Both people who test positive and negativ...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07630727 · Ausper Biopharma Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 March 2029
🇨🇳 CN

Who might be able to join this trial: - People who are able to fully understand and sign the consent form for the trial. - Men or women between 18 and 65 years of age (inclusive). - People whose body mass index (a measure of body weight relative to height) falls within the range set by the trial. - People who have had...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07709520 · Fujian Akeylink Biotechnology Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2026
🇨🇳 CN

Who might be able to join this trial: - People who are able to sign a consent form and fully understand what the trial involves, including its steps and possible side effects. - Men and women between the ages of 35 and 65 (inclusive) who are able to complete the trial as required. - People who do not plan to have child...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Hepatitis B. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

The Liver Foundation covers hepatitis B alongside its broader work on liver health.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.